Swiss Visio Retina Research Center
Active since 2019, it was recognised in 2022 as a member of the EuropeanVision Clinical Research Network of clinical research sites in ophthalmology.
The multidisciplinary team consists of 17 qualified members of staff:
- PD Dr méd. Aude Ambresin, founder and head of the research centre and principal investigator
- 3 Research Coordinators
- 2 Research Fellows
- 2 Photographers specialising in ophthalmological imaging
- 4 Clinical research nurses
- 3 Optometrists and orthoptists
- 1 Data Manager
- 1 Biostatistician
The centre is well represented at international congresses on ophthalmology and retina in particular, through oral presentations as an invited speaker and posters.
The Swiss Visio Retina Research Center is taking part in international multicentre Phase II, III and IV studies. Dr Ambresin is also initiating her own clinical studies, with the aim of expanding knowledge in the field of retinal pathologies and contributing to therapeutic innovation.
Find out about current studies
The SVRRC is also positioning itself as a centre of expertise for dry AMD.
In August 2023, a new consultation for patients suffering from dry AMD will open at Swiss Visio Montchoisi, to guarantee optimal care for these patients and to be able to offer them the new therapeutic options of light therapy and Syfovre® (pegcetacoplan), the first and only drug approved in the United States for dry AMD, which will soon be available in Switzerland.
A study of light therapy in patients with dry AMD is currently being set up in collaboration with a research team at EPFL.
